Bristol Myers Squibb (CELG-RI) EPS (Basic) Growth (1y) (2010 - 2026)
Powered by 
Analysis
Bristol Myers Squibb (CELG-RI) EPS (Basic) Growth (1y) (2010 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 641.39 Bn | 620.63 Bn | 17.26 Bn | -0.10% |
| 2 | AbbVie | 445.66 Bn | 439.09 Bn | 12.70 Bn | 284.05% |
| 3 | Merck | 357.45 Bn | 350.31 Bn | 12.21 Bn | -130.68% |
| 4 | Novartis Ag | 267.58 Bn | 259.89 Bn | 11.24 Bn | -15.94% |
| 5 | Pfizer | 156.75 Bn | 145.05 Bn | 10.94 Bn | -108.11% |
| 6 | Sanofi | 52.14 Bn | 44.75 Bn | 10.79 Bn | -91.06% |
| 7 | Revolution Medicines | 42.91 Bn | 42.91 Bn | - | - |
| 8 | Incyte | 24.62 Bn | 20.08 Bn | 1.57 Bn | 39.99% |
| 9 | United Therapeutics | 21.28 Bn | 18.62 Bn | 683.80 Mn | 13.91% |
| 10 | Bristol Myers Squibb | 232.18 Mn | -10.83 Bn | 9.25 Bn | 151.69% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 151.69% |
| Mar 31, 2026 | 8.44% |
| Dec 31, 2025 | 1,324.03% |
| Sep 30, 2025 | 79.95% |
| Jun 30, 2025 | -22.34% |
| Mar 31, 2025 | 120.59% |
| Dec 31, 2024 | -95.60% |
| Sep 30, 2024 | -36.28% |
| Jun 30, 2024 | -16.28% |
| Mar 31, 2024 | -645.01% |
| Dec 31, 2023 | -10.42% |
| Sep 30, 2023 | 24.72% |
| Jun 30, 2023 | 48.12% |
| Mar 31, 2023 | 80.65% |
| Dec 31, 2022 | -10.98% |
| Sep 30, 2022 | 7.79% |
| Jun 30, 2022 | 40.62% |
| Mar 31, 2022 | -34.11% |
| Dec 31, 2021 | 124.05% |
| Sep 30, 2021 | -15.94% |